News & events

Mark your calendar for the kick-off of the ECM Pharmacology Symposium Series!

On 17 January 2023 (11:00-12:30 EST), we will sponsor our first ECM Pharmacology Symposium Series session in close collaboration with our partner, The Extracellular Matrix Pharmacology Congress.

The session will include a stimulating talk by Professor Morten Karsdal on understanding the mysteries of the different types of collagens. Dr Alexander Lynge Reese-Petersen will then spotlight collagen type VI and its relationship to various pathologies, as well as the pharmacological and biological properties of the dangerous hormone Endotrophin.
 
Would you like to secure a virtual seat? Email bd@nordicbioscience.com and we will make sure you get an early bird pass to attend the symposium session.

Registration

Scientific topics

Extracellular matrix (ECM) dysregulation is the founding cause of tissue fibrosis, a process driving more than 50 pathologies and most chronic diseases. Fibrosis may develop both consequent to either an increase in tissue formation or a decrease in tissue degradation. ​​​​​​​Understanding the ECM and the central components of the basement membrane and interstitial ECM will lead to a better understanding of disease mechanisms and to novel treatment strategies. This may be a central part in precision medicine strategies to target the right patients.

Professor Morten Karsdal will talk about:

• ECM remodeling is the common denominator of all fibro-inflammatory disorders
• Collagens have signaling molecules that we need to understand to understand how the ECM affects cells in fibrosis and tissue turnover
• Endotrophin and other collagen fragments (Vastatin, Tumstatin and Endostatin) are potential signaling molecules derived from the processing of the collagens in the ECM
• Understanding ECM turnover may lead to better insight into disease mechanisms and better biological understanding of individual patients

Dr Alexander Reese’s presentation will cover:

• ECM biomarkers are elevated in chronic pathologies and have prognostic significance for outcome. How can we best use this to guide drug development?
• Endotrophin, a collagen hormone in multi-organ diseases
• Endotrophin in HFpEF, a potentially treatable high-risk endotype
• Use of the tissue turnover profile for patient selection

Early bird registrants will have a chance to win a copy signed by Professor Morten Karsdal of the second edition of Biochemistry of Collagens, Laminins and Elastin, a book dedicated to comprehensive ECM and collagen research.

Sign up today!